57473-32-2

Usage

Chemical Properties

Light Yellow Solid

InChI:InChI=1/C6H3Cl2N3/c7-4-3-5(8)11-2-1-9-6(11)10-4/h1-3H

Upstream product

• 1366126-57-9 C₆H₅N₃O₂ 
• 51647-90-6 imidazo[1,2-a]pyrimidine-5,7-diol 

Downstream Products

• 1366126-31-9 C₁₇H₁₆Cl₂N₄O₂ 
• 1366126-32-0 C₁₇H₁₆ClFN₄O₂ 
• 1366126-44-4 C₁₇H₁₅Cl₂FN₄O₂ 
• 1366126-24-0 C₁₇H₁₇FN₄O₂ 
• 1366126-25-1 C₁₇H₁₇ClN₄O₂ 
• 1366126-68-2 C₁₃H₉ClFN₃O 
• 1366126-69-3 C₁₃H₉ClFN₃O 
• 1366126-70-6 C₁₃H₉ClFN₃O 
• 1366126-71-7 C₁₃H₉Cl₂N₃O 
• 1366126-72-8 C₁₃H₉Cl₂N₃O 
• 1366126-74-0 C₁₄H₁₂ClN₃O 
• 1366126-26-2 C₁₇H₁₇ClN₄O₂ 
• 1366126-75-1 C₁₄H₁₂ClN₃O 
• 1366126-76-2 C₁₄H₉ClF₃N₃O 

Relevant academic research and scientific papers

LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin- 5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors

A series of PI3K-beta selective inhibitors, imidazo[1,2-a]-pyrimidin-5(1H)- ones, has been rationally designed based on the docking model of the more potent R enantiomer of TGX-221, identified by a chiral separation, in a PI3K-beta homology model. Synthesis and SAR of this novel chemotype are described. Several compounds in the series demonstrated potent growth inhibition in a PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage independent conditions.

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.

CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS

CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R' is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.